DS
RYTM icon

David Shaw’s Rhythm Pharmaceuticals RYTM Stock Holding History

David Shaw’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Sell
30,168
-2,484
-8% -$225K ﹤0.01% 2745
2026
Q1 		$2.84M Buy
32,652
+1,296
+4% +$126K ﹤0.01% 2638
2025
Q4 		$3.36M Buy
31,356
+27,771
+775% +$2.95M ﹤0.01% 2642
2025
Q3 		$362K Sell
3,585
-20,693
-85% -$1.92M ﹤0.01% 4021
2025
Q2 		$1.53M Sell
24,278
-59,591
-71% -$3.65M ﹤0.01% 2930
2025
Q1 		$4.44M Buy
83,869
+35,671
+74% +$1.98M ﹤0.01% 1983
2024
Q4 		$2.7M Buy
48,198
+43,904
+1,022% +$2.43M ﹤0.01% 2495
2024
Q3 		$225K Buy
+4,294
New +$206K ﹤0.01% 4107
2024
Q2 		– Sell
-10,462
Closed -$453K – 4801
2024
Q1 		$453K Sell
10,462
-118,030
-92% -$5.17M ﹤0.01% 3538
2023
Q4 		$5.91M Buy
+128,492
New +$4.05M 0.01% 1780
2023
Q2 		– Sell
-278,203
Closed -$4.96M – 4509
2023
Q1 		$4.96M Sell
278,203
-77,327
-22% -$1.94M 0.01% 1944
2022
Q4 		$10.4M Buy
355,530
+172,461
+94% +$4.43M 0.01% 1396
2022
Q3 		$4.49M Buy
183,069
+146,577
+402% +$2.73M 0.01% 2223
2022
Q2 		$151K Sell
36,492
-60,493
-62% -$331K ﹤0.01% 4637
2022
Q1 		$1.12M Buy
+96,985
New +$851K ﹤0.01% 3824
2021
Q2 		– Sell
-31,653
Closed -$673K – 4983
2021
Q1 		$673K Buy
+31,653
New +$918K ﹤0.01% 3364
2019
Q1 		– Sell
-10,982
Closed -$295K – 3878
2018
Q4 		$295K Sell
10,982
-41,179
-79% -$1.14M ﹤0.01% 3356
2018
Q3 		$1.52M Buy
52,161
+14,586
+39% +$461K ﹤0.01% 2391
2018
Q2 		$1.18M Buy
+37,575
New +$1.03M ﹤0.01% 2606

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

David Shaw's RYTM Position: Q2 2026 in Review

David Shaw reduced its Rhythm Pharmaceuticals (RYTM) stake by 7.6% in Q2 2026, selling an estimated $225K and leaving 30,168 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

David Shaw first reported a position in RYTM in Q2 2018 and has held it in 19 quarters since. The position peaked at $10.4M in Q4 2022. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • David Shaw held 30,168 shares of Rhythm Pharmaceuticals worth $3.35M as of Q2 2026.
  • David Shaw sold 2,484 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2745 holding.
  • David Shaw first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • David Shaw's Rhythm Pharmaceuticals position peaked at $10.4M in Q4 2022.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.